62123
document
Double-blind , placebo-controlled trial of risperidone plus amantadine in children with autism : a 10-week randomized study . OBJECTIVE This study aimed to investigate the effect of adding amantadine to risperidone for treatment of autism . METHODS Forty outpatients aged 4 to12 years , who were diagnosed with autism spectrum disorders based on the Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition , Text Revision criteria , were assigned to this double-blind clinical trial . The subjects were divided randomly into 2 groups . One group received risperidone plus amantadine , and the other group received risperidone plus placebo . The dose of risperidone was titrated between 1 and 2.0 mg/d , and the dose of amantadine was 100 or 150 mg/d for patients less than 30 kg or more than 30 kg , respectively . The patients were assessed using the Aberrant Behavioral Checklist-Community ( ABC-C ) and adverse effects checklist as well as clinical global impression-improvement ( CGI-I ) at2 checkpoints of 5-week intervals after the baseline . Informed consentwas obtained from the parents of each participant . RESULTS Among ABC-C subscales , Hyperactivity and Irritability showed significantly greater reduction in the amantadine group than the placebo group . There was no significant difference in adverse effects between the 2 groups . The CGI-I scores show significant improvement in the amantadine group compared to the placebo group . CONCLUSIONS The present study suggests that amantadine may be a potential adjunctive treatment strategy for autism and it was generally well tolerated .
62124
Intervention_Control
placebo-controlled
62125
Intervention_Pharmacological
risperidone plus amantadine
62126
Intervention_Pharmacological
amantadine to risperidone
62127
Intervention_Pharmacological
risperidone plus amantadine
62128
Intervention_Pharmacological
risperidone plus
62129
Intervention_Control
placebo
62130
Intervention_Pharmacological
amantadine
62131
Intervention_Pharmacological
amantadine
62132
Intervention_Pharmacological
amantadine
62133
Outcome_Mental
Aberrant Behavioral Checklist-Community ( ABC-C )
62134
Outcome_Adverse-effects
adverse effects checklist
62135
Outcome_Mental
clinical global impression-improvement ( CGI-I )
62136
Outcome_Mental
ABC-C subscales , Hyperactivity and Irritability
62137
Outcome_Adverse-effects
adverse effects
62138
Outcome_Mental
CGI-I scores
62139
Participant_Age
children
62140
Participant_Condition
autism
62141
Participant_Sample-size
Forty
62142
Participant_Age
aged 4 to12 years
62143
Participant_Condition
autism spectrum disorders